Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 3/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CCND1 | P24385 | 1/20 | 0.49 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10287528 | 0.89 | QDPR (0.54) | QDPRSLC6A4HTR6SIGMAR1 | |
| SCHEMBL7369176 | 0.84 | QDPR (0.72) | QDPRSLC6A4 | |
| SCHEMBL6785843 | 0.83 | QDPR (0.49) | QDPRSLC6A4HTR6SIGMAR1CCNB2 | |
| SCHEMBL14923997 | 0.81 | QDPR (0.64) | QDPR | |
| SCHEMBL11558057 | 0.81 | QDPR (0.56) | QDPRSLC6A4HTR6CCNB2CDK1 | |
| SCHEMBL578138 | 0.81 | QDPR (0.68) | QDPRSLC6A4SIGMAR1 | |
| SCHEMBL155267 | 0.81 | QDPR (0.68) | QDPRSLC6A4 | |
| SCHEMBL13898494 | 0.81 | QDPR (0.68) | QDPRSLC6A4HTR6 | |
| SCHEMBL1814323 | 0.81 | QDPR (0.68) | QDPR | |
| SCHEMBL8382616 | 0.81 | QDPR (1.00) | QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| US-10744155-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | UNIVERSITETET I OSLO (NO) | 2020-08-18 | — | — | US | disclosed |
| US-20190282606-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | UNIVERSITETET I OSLO (NO) | 2019-09-19 | — | — | US | disclosed |
| US-10322143-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | UNIVERSITETET I OSLO (NO) | 2019-06-18 | — | — | US | disclosed |
| US-20190161499-A1 | PESTICIDALLY ACTIVE 1,2,4-TRIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-05-30 | — | — | US | disclosed |
| US-9382243-B2 | Azabenzimidazole tetrahydropyran derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160158271-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | UNIVERSITETET I OSLO (NO) | 2016-06-09 | — | — | US | disclosed |
| US-20160158271-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | UNIVERSITETET I OSLO (NO) | 2016-06-09 | — | — | US | disclosed |
| US-20150210685-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-07-30 | — | — | US | disclosed |
| US-RE44205-E1 | Adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| EP-0863875-B1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | HOFFMANN LA ROCHE (CH) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
| US-5137889-A | Hypotensive agents; coronary vasodilators; calcium antagonists; antiinflammatory agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-11 | — | — | US | disclosed |
| US-5034395-A | Hypotensive agents, carboxylated dihydropyridines | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-23 | — | — | US | disclosed |
| EP-0145434-A2 | Novel dihydropyridine derivatives and process for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161499-A1 | PESTICIDALLY ACTIVE 1,2,4-TRIAZOLE DERIVATIVES | ACHE, AADAC, ATL3 | QDPR 1656/4885SLC6A4 4340/4885HTR6 3351/4885 |
| US-10322143-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | ADAMTS5, ADAMTS4, ADAMTS1 | QDPR 1778/4885SLC6A4 991/4885HTR6 1461/4885 |
| US-20150210685-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | PRKAG2, PRKAB2, PRKAG1 | QDPR 1293/4885SLC6A4 4774/4885HTR6 3823/4885 |
| US-20190282606-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | ADAMTS5, ADAMTS4, ADAMTS1 | QDPR 1778/4885SLC6A4 991/4885HTR6 1461/4885 |
| US-20160158271-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | ADAMTS5, ADAMTS4, ADAMTS1 | QDPR 1778/4885SLC6A4 991/4885HTR6 1461/4885 |
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | QDPR 405/4885SLC6A4 3264/4885HTR6 1665/4885 |
| US-10744155-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | ADAMTS5, ADAMTS4, ADAMTS1 | QDPR 1778/4885SLC6A4 991/4885HTR6 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.